DK1912673T3 - Fremgangsmåde til at binde effektor-molekyler til proteiner - Google Patents
Fremgangsmåde til at binde effektor-molekyler til proteinerInfo
- Publication number
- DK1912673T3 DK1912673T3 DK06744294.7T DK06744294T DK1912673T3 DK 1912673 T3 DK1912673 T3 DK 1912673T3 DK 06744294 T DK06744294 T DK 06744294T DK 1912673 T3 DK1912673 T3 DK 1912673T3
- Authority
- DK
- Denmark
- Prior art keywords
- protein
- effector molecules
- proteins
- binding effector
- cysteines
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 5
- 108090000623 proteins and genes Proteins 0.000 title abstract 5
- 239000012636 effector Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 235000018102 proteins Nutrition 0.000 abstract 4
- 239000003638 chemical reducing agent Substances 0.000 abstract 2
- 235000018417 cysteine Nutrition 0.000 abstract 2
- 150000001945 cysteines Chemical class 0.000 abstract 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Divinylene sulfide Natural products C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 238000011026 diafiltration Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0513852.4A GB0513852D0 (en) | 2005-07-06 | 2005-07-06 | Biological products |
| PCT/GB2006/002416 WO2007003898A1 (en) | 2005-07-06 | 2006-06-29 | Process for attaching effector molecules to proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1912673T3 true DK1912673T3 (da) | 2011-05-02 |
Family
ID=34856761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK06744294.7T DK1912673T3 (da) | 2005-07-06 | 2006-06-29 | Fremgangsmåde til at binde effektor-molekyler til proteiner |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8378073B2 (da) |
| EP (1) | EP1912673B1 (da) |
| JP (1) | JP5203188B2 (da) |
| CN (1) | CN101212984B (da) |
| AT (1) | ATE502650T1 (da) |
| AU (1) | AU2006264684B2 (da) |
| CA (1) | CA2613481C (da) |
| DE (1) | DE602006020878D1 (da) |
| DK (1) | DK1912673T3 (da) |
| ES (1) | ES2361096T3 (da) |
| GB (1) | GB0513852D0 (da) |
| PL (1) | PL1912673T3 (da) |
| PT (1) | PT1912673E (da) |
| SI (1) | SI1912673T1 (da) |
| WO (1) | WO2007003898A1 (da) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100107501A (ko) * | 2008-01-18 | 2010-10-05 | 메디뮨 엘엘씨 | 부위 특이적 접합을 위한 시스테인 조작 항체 |
| MX2011008697A (es) | 2009-02-17 | 2011-11-18 | Ucb Pharma Sa | Moleculas de anticuerpos que tiene especificidad para ox40 humano. |
| GB0904214D0 (en) | 2009-03-11 | 2009-04-22 | Ucb Pharma Sa | Biological products |
| GB0920127D0 (en) * | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
| CN103702699B (zh) | 2011-07-07 | 2016-08-17 | 诺沃—诺迪斯克有限公司 | 具有附加的剂量捕获和显示模块的药物输送注射笔 |
| CA2859755C (en) | 2011-12-23 | 2021-04-20 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
| ES2869309T3 (es) * | 2013-12-13 | 2021-10-25 | Novo Nordisk Healthcare Ag | Método para la conjugación de proteínas con tioéter |
| WO2015123265A1 (en) * | 2014-02-11 | 2015-08-20 | Seattle Genetics, Inc. | Selective reduction of proteins |
| GB201419184D0 (en) * | 2014-10-28 | 2014-12-10 | Adc Biotechnology Ltd | Method of synthesising biomolecule-effector/reporter-conjugates using affinity resins |
| US20160151511A1 (en) | 2014-12-02 | 2016-06-02 | Antriabio, Inc. | Proteins and protein conjugates with increased hydrophobicity |
| AR103172A1 (es) | 2014-12-22 | 2017-04-19 | Novartis Ag | Reducción selectiva de residuos de cisteina en anticuerpos il-17 |
| JP6807326B2 (ja) | 2014-12-22 | 2021-01-06 | ユーシービー バイオファルマ エスアールエル | タンパク質製造方法 |
| CA2981501A1 (en) | 2015-06-04 | 2016-12-08 | Antriabio, Inc. | Amine pegylation methods for the preparation of site-specific protein conjugates |
| MX2019009372A (es) * | 2017-02-08 | 2019-12-11 | Pfizer | Produccion a gran escala para cisteinas de anticuerpo protegidas y no protegidas y su uso en la conjugacion de proteinas terapeuticas. |
| US11364303B2 (en) | 2017-09-29 | 2022-06-21 | Pfizer Inc. | Cysteine engineered antibody drug conjugates |
| GB201919062D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Antibody |
| CN116802211A (zh) | 2020-12-07 | 2023-09-22 | Ucb生物制药有限责任公司 | 针对白介素-22的抗体 |
| US20240067758A1 (en) | 2020-12-07 | 2024-02-29 | UCB Biopharma SRL | Multi-specific antibodies and antibody combinations |
| AR125732A1 (es) | 2021-05-03 | 2023-08-09 | UCB Biopharma SRL | Anticuerpos anti-trem1 |
| GB202111905D0 (en) | 2021-08-19 | 2021-10-06 | UCB Biopharma SRL | Antibodies |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4728430A (en) * | 1986-02-10 | 1988-03-01 | Millipore Corporation | Diafiltration method |
| US5216183A (en) * | 1988-04-19 | 1993-06-01 | Teijin Limited | Cyclopentanone/cyclopentenone derivative |
| US5225194A (en) * | 1989-11-13 | 1993-07-06 | Ldc Research Corporation | Aqueous diafiltration process for preparing acellular vaccines, against selected bacterial diseases |
| AU1140495A (en) * | 1994-01-27 | 1995-08-03 | Bristol-Myers Squibb Company | Method for preparing thioether conjugates |
| US20040121415A1 (en) * | 1996-12-10 | 2004-06-24 | King David John | Monovalent antibody fragments |
| GB9625640D0 (en) * | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| DE19911329A1 (de) * | 1998-03-27 | 2000-09-21 | Benes Ivan Friedrich | Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung |
| GB9812545D0 (en) * | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
| CA2349363A1 (en) * | 1998-10-30 | 2000-05-11 | Nephros, Inc. | Non-isosmotic diafiltration system |
| US6146902A (en) * | 1998-12-29 | 2000-11-14 | Aventis Pasteur, Inc. | Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions |
| US6406631B1 (en) * | 1999-07-30 | 2002-06-18 | Nephros, Inc. | Two stage diafiltration method and apparatus |
| GB0303337D0 (en) * | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
| CN1621091A (zh) * | 2003-11-28 | 2005-06-01 | 付经国 | 聚乙二醇化轮状病毒体肠靶向制剂及其合成方法 |
| GB0425569D0 (en) * | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Biological products |
| US7908694B1 (en) * | 2008-09-24 | 2011-03-22 | Robert Sloane | Mattress cover apparatus with integrated seals |
-
2005
- 2005-07-06 GB GBGB0513852.4A patent/GB0513852D0/en not_active Ceased
-
2006
- 2006-06-29 ES ES06744294T patent/ES2361096T3/es active Active
- 2006-06-29 US US11/994,053 patent/US8378073B2/en active Active
- 2006-06-29 PL PL06744294T patent/PL1912673T3/pl unknown
- 2006-06-29 CA CA2613481A patent/CA2613481C/en active Active
- 2006-06-29 DK DK06744294.7T patent/DK1912673T3/da active
- 2006-06-29 PT PT06744294T patent/PT1912673E/pt unknown
- 2006-06-29 AT AT06744294T patent/ATE502650T1/de active
- 2006-06-29 WO PCT/GB2006/002416 patent/WO2007003898A1/en active Application Filing
- 2006-06-29 EP EP06744294A patent/EP1912673B1/en active Active
- 2006-06-29 SI SI200631002T patent/SI1912673T1/sl unknown
- 2006-06-29 CN CN2006800234116A patent/CN101212984B/zh active Active
- 2006-06-29 JP JP2008518969A patent/JP5203188B2/ja active Active
- 2006-06-29 AU AU2006264684A patent/AU2006264684B2/en active Active
- 2006-06-29 DE DE602006020878T patent/DE602006020878D1/de active Active
Also Published As
| Publication number | Publication date |
|---|---|
| SI1912673T1 (sl) | 2011-10-28 |
| US8378073B2 (en) | 2013-02-19 |
| US20080306246A1 (en) | 2008-12-11 |
| AU2006264684B2 (en) | 2011-11-03 |
| ATE502650T1 (de) | 2011-04-15 |
| CA2613481A1 (en) | 2007-01-11 |
| CN101212984B (zh) | 2011-09-28 |
| GB0513852D0 (en) | 2005-08-10 |
| PT1912673E (pt) | 2011-04-14 |
| EP1912673B1 (en) | 2011-03-23 |
| CA2613481C (en) | 2014-11-25 |
| CN101212984A (zh) | 2008-07-02 |
| WO2007003898A1 (en) | 2007-01-11 |
| WO2007003898A8 (en) | 2008-10-09 |
| DE602006020878D1 (de) | 2011-05-05 |
| ES2361096T3 (es) | 2011-06-13 |
| PL1912673T3 (pl) | 2011-07-29 |
| JP5203188B2 (ja) | 2013-06-05 |
| JP2008544976A (ja) | 2008-12-11 |
| AU2006264684A1 (en) | 2007-01-11 |
| EP1912673A1 (en) | 2008-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1912673T3 (da) | Fremgangsmåde til at binde effektor-molekyler til proteiner | |
| CY1124802T1 (el) | Δεσμευτικοι παραγοντες σκληροστινης | |
| ATE517917T1 (de) | Herstellung eines rekombinanten il-18-bindenden proteins | |
| BRPI0508610A (pt) | derivados de aminoácidos | |
| DE602005022830D1 (de) | Weniger immunogene bindungsmoleküle | |
| DK1951747T3 (da) | Fremgangsmåde og mellemprodukter til syntese af caspofungin | |
| BRPI0508969A (pt) | compostos orgánicos | |
| DE602006009789D1 (de) | Acetylenderivate | |
| EA200702193A1 (ru) | Гликозилирование белков | |
| EA200700400A1 (ru) | Производные n-(1h-индолил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии | |
| NO20082749L (no) | Fremgangsmate for fremstilling av ferri-succinylkasein | |
| WO2006079057A3 (en) | Methods and compositions for specific inhibition of protein splicing by small molecules | |
| ZA200800862B (en) | Cross-β structure binding compounds | |
| EA200701852A1 (ru) | Производные аминокислот | |
| ATE529433T1 (de) | Verfahren zur reinigung eines il-18-bindenden proteins | |
| WO2009138494A3 (en) | Amino acid sequences directed against toll-like receptors and their use for the treatment of diseases related to toll-like receptors | |
| NO20082989L (no) | Fremstiling av gamma-aminosyrer som har affinitet for alfa-2-deltaproteinet | |
| EA200870058A1 (ru) | Композиции, содержащие остеопонтин крупного рогатого скота, для улучшения процесса заживления ран | |
| TW200740769A (en) | Novel process | |
| ATE543097T1 (de) | Zellulärer rezeptor für antiproliferativen faktor | |
| ATE532502T1 (de) | Kosmetische zusammensetzung für das haar | |
| ATE458482T1 (de) | Verwendung von amino substituierten benzimidazolen | |
| ATE514679T1 (de) | Biarylcarboxyarylamide als modulatoren des vanilloid-1-rezeptors | |
| ITRM20050425A1 (it) | Processo per la produzione di prodotti a base di idrolizzati proteici in composizione con manganese. | |
| CY1109747T1 (el) | Μεθοδος διεργασιων για την παρασκευη αναστολεων τρυπτασης |